Ajinomoto Bio-Pharma Services vs Corden Pharma: CDMO Comparison
Side-by-side comparison of Ajinomoto Bio-Pharma Services and Corden Pharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Corden Pharma has FDA inspections on record (2); Ajinomoto Bio-Pharma Services does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Corden Pharma holds 9 active EMA GMP certificates; Ajinomoto Bio-Pharma Services does not appear in EudraGMDP.
- Ajinomoto Bio-Pharma Services maintains 1 MHRA / UK GMP certificate; Corden Pharma does not.
On a 13-modality CDMO landscape, both Ajinomoto Bio-Pharma Services and Corden Pharma qualify as Biologics manufacturers; Ajinomoto Bio-Pharma Services carries the higher composite Signal Score for Biologics programs in this comparison.
What to evaluate for Biologics programs
Both Ajinomoto Bio-Pharma Services and Corden Pharma qualify as Biologics CDMOs. When choosing between them for Biologics programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
Frequently asked: Ajinomoto Bio-Pharma Services vs Corden Pharma
Which has the stronger FDA inspection record, Ajinomoto Bio-Pharma Services or Corden Pharma?
Both Ajinomoto Bio-Pharma Services and Corden Pharma maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Ajinomoto Bio-Pharma Services has 0 FDA inspections on record; Corden Pharma has 2.
How do Ajinomoto Bio-Pharma Services and Corden Pharma compare on European GMP coverage?
Ajinomoto Bio-Pharma Services holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Corden Pharma holds 9 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Biologics manufacturing — Ajinomoto Bio-Pharma Services or Corden Pharma?
Both Ajinomoto Bio-Pharma Services and Corden Pharma are tagged as Biologics CDMOs in our directory, so both are credible options for Biologics programs. The most important differentiator for Biologics selection is typically scale & bioreactor fit: Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Ajinomoto Bio-Pharma Services carries a Signal Score of 86/100 and Corden Pharma carries 82/100 — essentially tied for Ajinomoto Bio-Pharma Services. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →